- Primary position:
- Lecturer in Clinical Neurosciences
Dr Newman was appointed as a lecturer in Clinical Neurosciences in 2010.
Dr Newman leads a multidisciplinary group that investigates fundamental mechanisms of neuronal injury along with new approaches to central nervous system therapy through the development and use of targeted nanoparticles.
The group is based in the life sciences building in the centre of the campus, their work relies on extensive multidisciplinary collaboration with colleagues across several departments in the University. They are actively pursuing translational research in their work on enhanced disease diagnosis.
Postgraduate Certificate in Academic Practice (FHEA)
PhD, University of Southampton
BSc, Biochemistry and Physiology
Lecturer, University of Southampton 2010 – present
Senior Research Fellow, Biological Sciences, 2006-2010
The University of Southampton's electronic library (e-prints)
The contribution of inflammation to outcomes in hearing loss.
Age related hearing loss affects a significant number of older people. Despite this and in common with other conditions with a neurodegenerative component, we lack disease-modifying drugs to treat the condition. With collaborators in ISVR (Verschuur, Lineton) we are exploring the contribution of the innate immune system to the rate of progression of hearing loss. A better understanding of the relationship between inflammatory markers and hearing function may enable us to stratify individuals such that we are able to determine those individuals most at risk of deterioration. Our current work includes investigating hearing and inflammation in a longitudinal human study of older community dwelling individuals.
A percentage of people experiencing hearing loss due to changes within their cochleae are recipients of cochlear implants. These devices are designed to transduce sounds from the outside world to the auditory pathways within the cochlea and brain. A small subset of the cohort, those with partial hearing loss, receive shorter electroacoustic implants. These implants replace the missing function in part of the cochlea and allow the residual hearing to remain functional. In both implant groups a small number of patients do not do as well as anticipated, we have a multi-centre study underway to explore the contribution of inflammation to this variation in outcome.
Biocompatible nanoparticles for enhanced drug delivery
The growing burden of neurological disease is driving a need to develop new routes for selective drug delivery to the central nervous system. We have developed targeted engineered nanoparticles for drug delivery. We use organic nanoparticles capable of delivering several different cargo types (hydrophilic, hydrophobic, and protein). These are being tested in vitro, and in vivo.
Through a combination of approaches we are investigating the interaction of the nanoparticles with neurons, and stem cells (Evans, Oreffo, FoM), including the uptake mechanisms and the factors that influence this. We are working to identify neuron-specific ligands to use as targeting moieties. We have developed fluorescence-based approaches to resolve the delivery kinetics, including the temporal profile, of compounds. Our current focus is the fate and clearance of the nanoparticles after internalization.
In collaboration with colleagues at the University of Malaya (Woo, Ariffin), and HDH (Cheong), we are exploiting these nanoparticles for enhanced delivery of compounds to the female reproductive tract.
Nanotoxicology – airborne particulates
As nanoparticle usage becomes more mainstream, in both medicine and consumer products, there is a need to investigate the possible detrimental impact of nanoparticles on the health and integrity of the CNS. Anthropogenic airborne nanoparticles may also be a challenge to the nervous system. Together with colleagues in the Centre for Biological Sciences (Poppy, Girling) we are investigating the impact of airborne nanoparticulate pollutants on learning and memory in the honey bee, an insect of significant ecological and economic importance.
A microfluidic multi-user platform for the study of neurodegeneration
Neurodegeneration is a component of many neurological conditions. Understanding the changes in pathways and cellular machinery as the pathology unfolds is essential if we are to develop new interventions to slow disease progression. Recent work has determined that different compartments within neurons behave and respond differently to each other during disease pathogenesis. There is a need for new experimental tools if we are to make inroads into understanding these fundamental mechanisms. Our group has used micro-fabrication techniques to develop a low cost, replacement protocols for organized neuronal cultures in vitro. The device is amenable for studies of the changes within the different cellular compartments of the neuron, including at the single cell level, in mono and mixed culture systems. The device is amenable to high-resolution imaging, and is accessible for electrophysiology and electrochemistry.
Academic unit: Clinical and Experimental Sciences
Promoting tissue regeneration by carrying drugs and molecules directly to stem cells.
Postgraduate student supervision
Year of entry 2010
Shilong Lu (FoM/FEE)
Year of entry 2011
Andrew Causon (FoM/FEE)
Christine Reitmayer (FoM/FNES)
Katerina Zisimopolou (FoM)
Year of entry 2012
Akosua Agyemang-Prempeh (FoM/FEE)
Year of entry 2013
Edoardo Scarpa (FoM)
Faculty of Medicine
Deputy Programme Lead of the Masters in Medical Science
MMedSc Deputy Programme Lead and Module Co-ordinator for MEDI4015/4014/6056/6057. Lectures and small group teaching.
BM5/BM4 Lectures, BMedSc project supervision, Personal tutor.
Project supervision on the BSc/MBiol/MMedSc/BMedSc.